Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

Medulla Communications Pvt. Ltd., one of the world's most awarded healthcare advertising agencies, has announced its ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Novartis, a New Jersey drug manufacturer, filed the lawsuit in federal court in Portland over the program that allows hospitals and community health centers to get some medications at discount prices.

Drugs to treat attention deficit hyperactivity disorder were linked to a reduced risk of suicidal behavior, substance misuse and criminality in the first research of its kind.

The company is shifting some production from China and Mexico in a move that could soften the impact of tariffs.

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

The European Union could not say when a joint statement on tariffs with the United States would be ready, nor when the White House would issue an executive or ...

The clean-up bill for Swiss pharma giant Roche’s former manufacturing site in Co Clare now totals €150.5m in what the company ...